Compare ANIP & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | INNV |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 1999 | 2021 |
| Metric | ANIP | INNV |
|---|---|---|
| Price | $75.10 | $9.76 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 3 |
| Target Price | ★ $105.78 | $12.00 |
| AVG Volume (30 Days) | 314.1K | ★ 475.4K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 419.23 | 90.91 |
| EPS | ★ 3.86 | 0.14 |
| Revenue | $206,547,000.00 | ★ $989,707,000.00 |
| Revenue This Year | $24.85 | $8.51 |
| Revenue Next Year | $10.76 | $7.99 |
| P/E Ratio | ★ $18.56 | $69.93 |
| Revenue Growth | 2.47 | ★ 15.93 |
| 52 Week Low | $69.58 | $4.53 |
| 52 Week High | $95.45 | $12.64 |
| Indicator | ANIP | INNV |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 59.24 |
| Support Level | $69.93 | $7.33 |
| Resistance Level | $74.29 | $12.05 |
| Average True Range (ATR) | 1.83 | 0.43 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 38.27 | 67.33 |
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.